Alitretinoin
From Wikipedia, the free encyclopedia
 |
|
|
Alitretinoin
|
|
| Systematic (IUPAC) name | |
| (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl- 1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H28O2 |
| Mol. mass | 300.435 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Rx only |
| Routes | Topical |
Alitretinoin (tradename Panretin) is an antineoplastic agent developed by Ligand Pharmaceuticals.
It is a first generation retinoid.
[edit] Clinical uses
Alitretinoin is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. It is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using alitretinoin with systemic anti-KS treatment.
[edit] History
Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.
[edit] External links
- Prescribing Information (revised February 2007). Retrieved on 01-30-08.
|
|||||||||||
